Literature DB >> 15197554

Expression profiles of fibrinolytic components in nasal mucosa.

Takayuki Sejima1, Seiji Madoiwa, Jun Mimuro, Teruko Sugo, Takashi Ishida, Keiichi Ichimura, Yoichi Sakata.   

Abstract

Components of the fibrinolytic pathway contribute to diverse pathways in many tissues, in addition to their well-recognized role in degradation of fibrin clots. In this study of nasal mucosa, we investigated the presence of mRNA of tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA), plasminogen activator inhibitor-1 (PAI-1), and plasminogen activator inhibitor-2 (PAI-2) using reverse transcription polymerase chain reaction (RT-PCR) and in situ hybridization, and compared these results with their localization in immunostained tissues. According to real-time RT-PCR results, t-PA, u-PA, PAI-1, and PAI-2 mRNA were noted in human nasal mucosa. Particularly, expression of u-PA and PAI-1 mRNA was significantly high in allergic nasal mucosa in comparison with normal mucosa. t-PA mRNA was detected in endothelial cells and epithelium in normal nasal mucosa. t-PA mRNA was detected in mucous cells of allergic submucosal glands, but not in normal glands. In allergic rhinitis, u-PA and PAI-2 mRNA were detected in mucinous cells and epithelium, and PAI-1 mRNA was detected in serous cells and epithelium. Expression of u-PA and PAI-1 mRNA in normal nasal tissues was decreased in contrast to that in allergic nasal tissues. u-PA staining was observed in mucous cells of allergic submucosal glands and the staining pattern of PAI-2 was similar to that of u-PA. PAI-1 was present in serous cells of submucosal glands from allergy samples, while epithelial cells were almost devoid of stain. In contrast, with allergy, immunohistochemical staining of t-PA was negative in submucosal glands, though positive in endothelial cells and epithelium. However, the expression of t-PA mRNA in allergic nasal mucosa was noted in mucous cells. In fibrin autography of nasal discharge, u-PA was markedly activated in the allergic patient. These results suggest that t-PA synthesized in mucous cells is promptly secreted and modifies watery nasal discharge in allergic rhinitis, and that u-PA activity may help the passage of large amounts of rhinorrhea by also reducing its viscosity. A lot of cellular infiltration (eosinophils in particular) was recognized in allergic nasal mucosa. It is most likely that the modifications in expression of PAs and PAIs are due to the local release of cytokines or growth factors from these inflammatory and immune cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197554     DOI: 10.1007/s00418-004-0664-2

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  38 in total

1.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 3.  Plasminogen activator inhibitors--a review.

Authors:  E K Kruithof
Journal:  Enzyme       Date:  1988

4.  Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay.

Authors:  I Bièche; I Laurendeau; S Tozlu; M Olivi; D Vidaud; R Lidereau; M Vidaud
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

5.  Plasminogen activators in human nasal polyps and mucosa.

Authors:  K Larsen; M P de Maat; J Jespersen
Journal:  Rhinology       Date:  1997-12       Impact factor: 3.681

6.  Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas.

Authors:  J Nakayama; H Tahara; E Tahara; M Saito; K Ito; H Nakamura; T Nakanishi; E Tahara; T Ide; F Ishikawa
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

7.  PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model.

Authors:  Chad K Oh; Barbara Ariue; Rodrigo F Alban; Bryan Shaw; Seong H Cho
Journal:  Biochem Biophys Res Commun       Date:  2002-06-28       Impact factor: 3.575

8.  Studies of the mechanism of the periodic acid-Schiff histochemical reaction for glycogen using infrared spectroscopy and model chemical compounds.

Authors:  G S Nettleton; A M Carpenter
Journal:  Stain Technol       Date:  1977-03

9.  Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.

Authors:  Y Sakata; M Okada; A Noro; M Matsuda
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

10.  Fibrinolytic components in nasal mucosa and nasal secretion.

Authors:  T Yasuda; Y Sakata; S Madoiwa; J Mimuro; M Matsuda; K Kitamura
Journal:  Histochem Cell Biol       Date:  1998-11       Impact factor: 4.304

View more
  3 in total

1.  Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome.

Authors:  Alicja Kasperska-Zajac; Barbara Rogala
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

2.  Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression.

Authors:  Tetsuji Takabayashi; Atsushi Kato; Anju T Peters; Kathryn E Hulse; Lydia A Suh; Roderick Carter; James Norton; Leslie C Grammer; Seong H Cho; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

Review 3.  News and views in Histochemistry and Cell Biology.

Authors:  Esther Asan; Detlev Drenckhahn
Journal:  Histochem Cell Biol       Date:  2004-12-22       Impact factor: 2.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.